{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:42:45Z","timestamp":1792028565289,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00280-011-1582-3","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T21:45:52Z","timestamp":1297892752000},"page":"967-969","source":"Crossref","is-referenced-by-count":21,"title":["Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFR\u03b1-positive chronic eosinophilic leukaemia"],"prefix":"10.1007","volume":"67","author":[{"given":"Grzegorz","family":"Helbig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Moskwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Piszcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Swiderska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Urbanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ca\u0142becka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Sefery\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ra\u017any","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Rodzaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"\u017buk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomira","family":"Kyrcz-Krzemie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,17]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, De Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201\u20131214","journal-title":"N Engl J Med"},{"key":"1582_CR2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","volume":"92","author":"M Baccarani","year":"2007","unstructured":"Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR\u03b1 positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173\u20131179","journal-title":"Haematologica"},{"key":"1582_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-0609.2006.00652.x","volume":"76","author":"G Helbig","year":"2006","unstructured":"Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J et al (2006) The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76:535\u2013536","journal-title":"Eur J Haematol"},{"key":"1582_CR4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","volume":"18","author":"P Vandenberghe","year":"2004","unstructured":"Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D et al (2004) Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemia. Leukemia 18:734\u2013742","journal-title":"Leukemia"},{"key":"1582_CR5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","volume":"143","author":"G Metzgeroth","year":"2008","unstructured":"Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C et al (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome-a phase-II study. Brit J Haematol 143:707\u2013715","journal-title":"Brit J Haematol"},{"key":"1582_CR6","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","volume":"110","author":"AD Klion","year":"2007","unstructured":"Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S et al (2007) Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 110:3552\u20133556","journal-title":"Blood"},{"key":"1582_CR7","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","volume":"109","author":"J Jovanovic","year":"2007","unstructured":"Jovanovic J, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G et al (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular response and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 109:4635\u20134641","journal-title":"Blood"},{"key":"1582_CR8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","volume":"23","author":"E Lierman","year":"2009","unstructured":"Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J et al (2009) FIP1L1-PDGFR\u03b1 D842\u00a0V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGF T674I eosinophilic leukaemia with single agent sorafenib. Leukemia 23:845\u2013851","journal-title":"Leukemia"},{"key":"1582_CR9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2141.2008.07546.x","volume":"145","author":"G Helbig","year":"2009","unstructured":"Helbig G, Moskwa A, \u015awiderska A, Urbanowicz A, Ca\u0142becka M, Gajkowska J et al (2009) Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: ectended follow-up. Brit J Haematol 145:132\u2013134","journal-title":"Brit J Haematol"},{"key":"1582_CR10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","volume":"27","author":"K Titier","year":"2005","unstructured":"Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P et al (2005) Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 27:634\u2013640","journal-title":"Ther Drug Monit"},{"key":"1582_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V114.22.22.22","volume":"114","author":"M Rondoni","year":"2009","unstructured":"Rondoni M, Ottaviani E, Cilloni D, Piccaluga P, Paolini S, Iacobucci I et al (2009) Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement: the response to imatinib is durable. A report of 33 patients with a follow-up of 30 to 92\u00a0months. Blood 114:22 (abstract 3894)","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00280-011-1582-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T16:33:24Z","timestamp":1592325204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1582-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,17]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1582-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,17]]}}}